Equillium Financials

EQ Stock  USD 1.55  0.01  0.64%   
Based on the analysis of Equillium's profitability, liquidity, and operating efficiency, Equillium is not in a good financial situation at this time. It has a very high odds of going through financial crisis in June. At this time, Equillium's Long Term Debt is relatively stable compared to the past year. As of 05/21/2024, Cash And Short Term Investments is likely to grow to about 63 M, while Property Plant And Equipment Net is likely to drop slightly above 682.7 K. Key indicators impacting Equillium's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio1.71.7898
Notably Down
Slightly volatile
The financial analysis of Equillium is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Equillium includes many different criteria found on its balance sheet. For example, investors should never minimize Equillium's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Equillium's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Equillium.

Net Income

(14 Million)

With this module, you can analyze Equillium financials for your investing period. You should be able to track the changes in Equillium individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past Equillium Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Equillium's financial statements are interrelated, with each one affecting the others. For example, an increase in Equillium's assets may result in an increase in income on the income statement.
The data published in Equillium's official financial statements usually reflect Equillium's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Equillium. For example, before you start analyzing numbers published by Equillium accountants, it's critical to develop an understanding of what Equillium's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Equillium's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Equillium's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Equillium's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Equillium. Please utilize our Beneish M Score to check the likelihood of Equillium's management manipulating its earnings.

Equillium Stock Summary

Equillium competes with Lyra TherapeuticsInc, Hookipa Pharma, Jasper Therapeutics, SAB Biotherapeutics, and Anebulo Pharmaceuticals. Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. Equillium operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.
Foreign Associate
  Canada
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS29446K1060
CUSIP29446K106
LocationCalifornia; U.S.A
Business Address2223 Avenida De
SectorBiotechnology
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.equilliumbio.com
Phone858 240 1200
CurrencyUSD - US Dollar
You should never invest in Equillium without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Equillium Stock, because this is throwing your money away. Analyzing the key information contained in Equillium's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Equillium Key Financial Ratios

Generally speaking, Equillium's financial ratios allow both analysts and investors to convert raw data from Equillium's financial statements into concise, actionable information that can be used to evaluate the performance of Equillium over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Equillium reports annually and quarterly.

Equillium Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets55.5M85.4M85.4M78.4M50.5M67.5M
Other Current Liab2.0M2.8M5.9M(6.1M)6.7M7.0M
Other Liab200K127K54K10.4M11.9M12.5M
Net Tangible Assets41.8M69.9M66.5M31.9M36.7M50.0M
Net Debt(3.5M)(15.7M)(40.4M)(48.9M)(22.4M)(23.5M)
Retained Earnings(41.1M)(70.9M)(110.0M)(172.4M)(185.7M)(176.5M)
Accounts Payable1.9M2.8M1.2M17.3M4.7M4.6M
Cash13.2M24.0M50.4M59.1M23.2M32.3M
Long Term Debt9.7M8.3M8.8M3.2M3.7M7.0M
Capital Surpluse80.4M82.9M141.1M176.6M203.1M105.8M
Other Current Assets2.4M3.3M3.0M3.4M2.2M2.4M
Total Liab13.7M15.6M18.9M46.5M28.0M21.1M
Net Invested Capital51.5M79.8M8.8M40.9M22.6M31.3M
Total Current Assets55.5M85.4M83.8M77.2M49.3M66.9M
Net Working Capital51.5M77.9M74.8M44.7M21.8M20.7M
Common Stock789.01K2K3K3.5K1.9K
Other Assets(108K)(254K)153K3.4M1.00.95

Equillium Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Equillium's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Income1.4M476K57K420K2.0M2.1M
Interest Expense279K1.1M1.1M1.1M491K748.9K
Gross Profit(23K)(45K)(72K)15.6M36.0M37.8M
Operating Income(26.7M)(29.5M)(37.8M)(62.1M)(14.5M)(15.2M)
Ebit(26.7M)(29.5M)(37.8M)(62.1M)(14.5M)(15.2M)
Research Development17.6M19.4M26.4M37.5M37.0M22.7M
Cost Of Revenue23K45K72K118K126K132.3K
Income Before Tax(25.6M)(29.8M)(39.1M)(62.4M)(12.8M)(13.4M)
Net Income(25.6M)(29.8M)(39.0M)(107.7M)(13.3M)(14.0M)
Income Tax Expense(23K)(45K)(72K)45.3M580K551K
Net Interest Income1.1M(623K)(1.0M)(633K)1.3M1.3M
Ebitda(26.7M)(29.5M)(37.7M)(16.0M)(14.4M)(15.1M)

Equillium Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Equillium. It measures of how well Equillium is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Equillium brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Equillium had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Equillium has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201920202021202220232024 (projected)
Investments(2.1M)(18.6M)27.5M18.7M7.8M8.2M
Change In Cash(15.3M)10.8M26.4M8.7M(35.9M)(34.1M)
Depreciation23K45K72K118K126K132.3K
Capital Expenditures74K202K57K279K50K47.5K
Net Income(25.6M)(29.8M)(39.1M)(62.4M)(13.3M)(14.0M)
End Period Cash Flow13.2M24.0M50.4M59.1M23.2M32.3M
Change To Netincome2.2M3.6M4.7M28.3M32.5M34.1M
Free Cash Flow(23.0M)(24.8M)(32.1M)(9.0M)(21.8M)(22.9M)
Other Non Cash Items47K341K237K48.7M(10.2M)(9.7M)

Equillium Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Equillium's current stock value. Our valuation model uses many indicators to compare Equillium value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Equillium competition to find correlations between indicators driving Equillium's intrinsic value. More Info.
Equillium is rated below average in return on equity category among related companies. It is rated # 2 in return on asset category among related companies . At this time, Equillium's Return On Equity is relatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Equillium by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Equillium's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Equillium's earnings, one of the primary drivers of an investment's value.

Equillium Systematic Risk

Equillium's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Equillium volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Equillium correlated with the market. If Beta is less than 0 Equillium generally moves in the opposite direction as compared to the market. If Equillium Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Equillium is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Equillium is generally in the same direction as the market. If Beta > 1 Equillium moves generally in the same direction as, but more than the movement of the benchmark.

About Equillium Financials

What exactly are Equillium Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Equillium's income statement, its balance sheet, and the statement of cash flows. Potential Equillium investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Equillium investors may use each financial statement separately, they are all related. The changes in Equillium's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Equillium's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze Equillium Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Equillium is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Equillium has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Equillium's financials are consistent with your investment objective using the following steps:
  • Review Equillium's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Equillium's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Equillium's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Equillium's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

Equillium Thematic Clasifications

Equillium is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Pharmaceutical ProductsView
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Equillium Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Equillium's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Equillium growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0203

At this time, Equillium's Price Earnings To Growth Ratio is relatively stable compared to the past year.

Equillium May 21, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Equillium help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Equillium. We use our internally-developed statistical techniques to arrive at the intrinsic value of Equillium based on widely used predictive technical indicators. In general, we focus on analyzing Equillium Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Equillium's daily price indicators and compare them against related drivers.
When determining whether Equillium is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Equillium Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Equillium Stock. Highlighted below are key reports to facilitate an investment decision about Equillium Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Equillium. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.
To learn how to invest in Equillium Stock, please use our How to Invest in Equillium guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Complementary Tools for Equillium Stock analysis

When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Is Equillium's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Equillium. If investors know Equillium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Equillium listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.35)
Revenue Per Share
1.085
Quarterly Revenue Growth
0.204
Return On Assets
(0.14)
Return On Equity
(0.48)
The market value of Equillium is measured differently than its book value, which is the value of Equillium that is recorded on the company's balance sheet. Investors also form their own opinion of Equillium's value that differs from its market value or its book value, called intrinsic value, which is Equillium's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Equillium's market value can be influenced by many factors that don't directly affect Equillium's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Equillium's value and its price as these two are different measures arrived at by different means. Investors typically determine if Equillium is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Equillium's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.